PMID- 22965928
OWN - NLM
STAT- MEDLINE
DCOM- 20130103
LR  - 20181202
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 87
IP  - 11
DP  - 2012 Nov
TI  - Comparative rates of adverse events with different formulations of intravenous 
      iron.
PG  - E123-4
LID - 10.1002/ajh.23322 [doi]
AB  - Oral iron replacement is the standard therapy in iron-deficiency anemia (IDA). 
      However, 59% of patients have gastrointestinal toxicity. With impaired iron 
      uptake from the gastrointestinal tract (in anemia of chronic disease (ACD) or 
      after bariatric surgery), suboptimal responsiveness to exogenous erythropoietin 
      (in chronic renal failure), in patients with cancer receiving chemotherapy, or 
      when oral iron is poorly tolerated, IV iron therapy is the preferred mode of 
      repletion. Although effective in increasing hemoglobin, the relative safety of 
      the available IV iron preparations is not well documented. We examined the 
      comparative safety of IV iron formulations used at hospitals associated with our 
      institution. Among 619 unique patients who received IV iron over a 2-year period, 
      we found 32 adverse events (AEs), ranging from urticaria to chest pain. There 
      were no serious AEs or anaphylactic-type reactions. In a multivariate model, 
      there was no difference in AE rates between low-molecular-weight iron dextran 
      (LMWD) and ferric gluconate; however, iron sucrose had significantly higher odds 
      ratio of AEs (OR = 5.7; 95% CI = 1.6-21.3). Our data suggest that AE rates with 
      IV iron are acceptable. More widespread use of LMWD, in particular, which can be 
      given safely as a total dose infusion (TDI), should be considered.
FAU - Okam, Maureen M
AU  - Okam MM
AD  - Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA. 
      mokam@partners.org
FAU - Mandell, Elyse
AU  - Mandell E
FAU - Hevelone, Nathanael
AU  - Hevelone N
FAU - Wentz, Rachel
AU  - Wentz R
FAU - Ross, Ainsley
AU  - Ross A
FAU - Abel, Gregory A
AU  - Abel GA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20120911
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
RN  - 0 (Ferric Compounds)
RN  - 0 (Hematinics)
RN  - 0 (Hemoglobins)
RN  - 9004-66-4 (Iron-Dextran Complex)
RN  - FZ7NYF5N8L (Ferric Oxide, Saccharated)
RN  - QLZ991V4A2 (Glucaric Acid)
RN  - W108RK810P (ferric gluconate)
SB  - IM
MH  - Anemia, Iron-Deficiency/blood/*drug therapy
MH  - Female
MH  - Ferric Compounds/administration & dosage/*adverse effects/therapeutic use
MH  - Ferric Oxide, Saccharated
MH  - Glucaric Acid/administration & dosage/*adverse effects/therapeutic use
MH  - Hematinics/administration & dosage/*adverse effects/therapeutic use
MH  - Hemoglobins/analysis
MH  - Humans
MH  - Injections, Intravenous
MH  - Iron-Dextran Complex/administration & dosage/*adverse effects/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Retrospective Studies
EDAT- 2012/09/12 06:00
MHDA- 2013/01/04 06:00
CRDT- 2012/09/12 06:00
PHST- 2012/07/31 00:00 [received]
PHST- 2012/08/06 00:00 [accepted]
PHST- 2012/09/12 06:00 [entrez]
PHST- 2012/09/12 06:00 [pubmed]
PHST- 2013/01/04 06:00 [medline]
AID - 10.1002/ajh.23322 [doi]
PST - ppublish
SO  - Am J Hematol. 2012 Nov;87(11):E123-4. doi: 10.1002/ajh.23322. Epub 2012 Sep 11.